The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01F | Monoclonal antibodies and antibody drug conjugates | |
4
|
L01FF | PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors | |
5
|
L01FF02 | Pembrolizumab |
| Active Ingredient |
|---|
|
Pembrolizumab is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. |
| Document | Type | Information Source | |
|---|---|---|---|
| KEYTRUDA Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.